Tag: Pharmaceuticals

pH Meters Market Size To Reach $1.95 Billion By 2022

Global pH meters market is expected to reach nearly USD 1,951.2 million by 2022 according to a new report by Grand View Research Inc. Key factors attributing to the market growth are introduction of technologically advanced portable and bench top pH meters, growing concerns to monitor environmental pollution and the need to regulate pH levels in various consumable products. 

Increasing demand for quality control and routine testing of soil, water, food, beverage, and dairy products is driving the use of new generation pH meters with multi-parameter analysis. The new devices are improving the efficiency, accuracy, ease of usage, and cost-effectiveness, which are expected to serve as high-impact rendering drivers over the forecast period. 

Increasing awareness regarding the need to regulate waste water pH in industries such as chemicals, pharmaceuticals, food processing, and other end use sectors is a key factor boosting the usage rates. pH neutralization of the waste water discharged from these industries is critical to prevent corrosion of sewage pipes and prevent leakage of harmful substances in to the land and other water bodies. 

Furthermore, growing awareness about soil pH and its impact on plant nutrient absorption is a key factor boosting the soil pH analysis. Maintaining the appropriate ratio of nitrogen, phosphorous, and potassium (N-P-K) in the soil plays an important role in improving the product yield, quality, and also improves resistance to various diseases. The shift towards scientific agricultural practices and growing demand for organic farming, soil testing, irrigational water testing, are some the key factors expected to positively reinforce market growth over the forecast period. 

Click the link below:
http://www.grandviewresearch.com/industry-analysis/ph-meter-market

Further key findings from the study suggest:

  • In 2014, bench top pH meters were the largest segment accounting for nearly 57% of the market. Bench top pH meters are widely used in different industries, research labs and commercial testing centers owing to their advanced features, ease of operation, durability of the sensors, and accuracy.
  • Portable pH meters are expected to be the fastest growing segment over the forecast period. Low cost of these devices, high accuracy and ability to monitor pH of samples at any location are major factors expected to boost the usage rates in the next seven years.
  • In 2014, Europe dominated the overall pH meters market with nearly 34% share. Some key factors attributed to the high share are presence of stringent environmental regulations, awareness about scientific agricultural, food and beverage manufacturing practices.
  • However, Asia Pacific is expected to the fastest growing with a CAGR of 7.9% over the forecast period. The shift from traditional agricultural practices to scientific and organic farming, increasing emphasis on managing waste water discharge, and increasing demand from academic, food processing, beverages and other end use industries are key factors expected to reinforce the market growth over the forecast period.
  • The market is witnessing high competition due to the presence of a large number of small and medium scale manufacturers catering to regional demand. Key market players include Thermo Fisher Scientific, Danaher Corporation, Mettler Toledo, Metrohm USA, Hanna Instruments, Agilent Technologies, and Perkin Elmer. 

Controlled Release Drug Delivery Market Worth $69.8 Billion By 2027

The global controlled release drug delivery market size is estimated to reach USD 69.8 billion by 2027 registering a CAGR of 7.8% during the forecast period, according to a new report by Grand View Research, Inc. The benefits associated with controlled release drug delivery systems, such as increased therapeutic efficacy, less side effects, and low treatment cost are the factors driving the market growth.

These technologies offer various benefits over traditional delivery forms, such as reduced dosage and dosage frequency, enhanced patient compliance, less gastrointestinal side effects, uniform drug effect, improved drug efficacy and safety, and reduced fluctuation of plasma drug levels.

Presence of multiple in-vivo biological barriers that affects the absorption, bioavailability, and stability of the drug has open wide horizon for the controlled release drug delivery products. For instance, controlled release drug delivery system has enabled delivery of even large and complex molecules such as DNA/RNA, proteins and polypeptides. Additionally, the rising awareness among healthcare professionals, regarding the advantage of controlled release drug delivery systems over conventional systems is expected to drive the demand for the market in long run.

Rapidly increasing geriatric and pediatric population is one of the major factors fueling the demand for controlled release drug delivery systems, due to high cases prescription non-adherence in this age-group. Innovations in various drug delivery systems has been providing geriatric and pediatric population with easy solutions, which are further propelling the market. Controlled release of drug delivery systems can be altered according to required dosage over a specific period of time.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/controlled-release-drug-delivery-market

Further key findings from the report suggest:

  • Based on application, oral controlled release systems held the largest market share in 2019 owing to increasing usage and ease of convenience offered for administration of medication
  • Targeted drug delivery is poised to be the fastest growing technology segment during the forecast period owing to various benefits of the technology, such as increased safety and therapeutic efficacy
  • Osmotic delivery is projected to witness the fastest CAGR in the activation modulation drug delivery systems during the forecast period, due to the ability of this release mechanism to not be affected by various factors, such as pH, food consumption, and gastrointestinal motility
  • North America held the largest market share in 2019 owing to the presence of developed healthcare infrastructure facilities, increasing R&D activities and existence of major market players
  • Asia Pacific is expected to post the highest CAGR during the forecast period owing to rising investments by dominant players in the region along with developments in the of pharmaceutical industry in emerging countries, such as India and China
  • Some of the prominent companies operating in the controlled release drug delivery market are Orbis Biosciences, Inc.; Merck and Co., Inc.; Alkermes plc; Johnson and Johnson; Coating Place, Inc.; Corium International, Inc.; Depomed, Inc.; Pfizer, Inc; Aradigm Corporation; and Capsugel

Enteral Feeding Formulas Market Size Worth $8.72 Billion By 2027

The global enteral feeding formulas market size is expected to reach USD 8.72 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 6.0% from 2020 to 2027. Increasing prevalence of diseases such as diabetes, cancer, dementia, multiple sclerosis, chronic liver disease and COPD is expected to boost the demand for enteral products that aid patients having trouble in oral intake. As per a study published by Cancer Research U.K., approximately 17.0 million new cancer cases were reported in 2018 across the globe. Incidence of cancer is projected to increase by 62% between 2018 and 2040.

In addition, growing deficiency of macro and micro nutrients among the patients in hospitals during pre and post-surgery drives the demand for enteral feeding formulas. Furthermore, increasing product offerings aimed at specific indications are delivering targeted nutritional needs, which is a key driver of this market. These enteral tube feeds usually contain polysaccharides and proteins for patients capable of digesting and absorbing nutrients without any difficulty. Availability of wide varieties of enteral formulas, along with increased demand for low-cost nutrient formulations among consumers, is boosting the market growth. Moreover, favorable reimbursement scenario supports high adoption of tube feeds among hospital patients as the enteral nutrition is usually covered under Medicare claims.

Moreover, the market is consolidated with presence of few leading players, including Nestle Health Science, Abbott, and Danone. These players are constantly investing in the R&D activities for development of enhanced products that cater to the niche therapeutic areas having high growth potential in the industry in order to gain a competitive edge. Market entry has proved to be challenging for new entrants as the industry is dominated by few major MNCs with high brand recognitions.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/enteral-feeding-formulas-market

Further key findings from the report suggest:

  • Standard formula emerged as the leading product segment in 2019 with a revenue share of 54.3% in the global market
  • By flow type, intermittent feeding flow accounted for the largest revenue share in 2019. Continuous feeding flow is projected to expand at the fastest CAGR during the forecast period
  • The adults stage segment accounted for the largest revenue share in 2019 owing to growing demand for such nutrition formulations in the adult population
  • Others emerged as the leading indication segment in 2019 with a revenue share of 41.9% in the global market
  • Home care emerged as the leading end user segment in 2019 and is expected to witness significant growth over the forecast period
  • North America accounted for the largest share in 2019 due to growing preference for home-based enteral therapy in the region.

Pulmonary Arterial Hypertension Market Size Worth $9.8 Billion By 2027

The global pulmonary arterial hypertension market size is expected to reach USD 9.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 5.6% over the forecast period. Increasing prevalence rates of pulmonary arterial hypertension (PAH) and government support for the development of orphan drugs drive the market growth.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of PAH has been increasing due to risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Moreover, the geriatric population is more prone to PAH and associated diseases owing to reduced immune function. According to the National Council on Aging (NCOA), about 80 percent of the population aged 65 and above have at least one chronic condition such as high cholesterol, diabetes, heart or kidney disease, or chronic obstructive pulmonary disease.

Government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983, are also anticipated to support the market for treatment drugs for PAH. These acts play a significant role in promoting the ethical usage and distribution of orphan drugs. The development of orphan drugs is promoted by the National Organization of Rare Disorders.

Robust drug pipeline and new product combinations awaiting approval or launch are anticipated to increase the PAH market competitiveness over the forecast period. In September 2019, Acceleron Pharma, a leading biopharmaceutical company, received FDA orphan drug designation for sotatercept for the treatment of pulmonary arterial hypertension.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/pulmonary-arterial-hypertension-market

Further key findings from the report suggest:

  • Prostacyclin and its analogs for treating PAH are projected to show lucrative growth over the forecast period. The sales of these drugs are anticipated to increase due to the growing use of oral prostacyclin agents
  • North America dominated the PAH market with a share of over 55.0% in 2019. This is attributed to the well-established infrastructure for the development and distribution of high-quality therapies and the availability of reimbursement for PAH therapies
  • Asia Pacific is estimated to register the highest CAGR of more than 6.0% over the forecast period due to its huge population base, rapid economic development, and improving healthcare system. Moreover, the high burden of diseases such as HIV in the region contribute to the development of PAH
  • The major players in the pulmonary arterial hypertension market that offer treatment solutions for PAH include GlaxoSmithKline plc; Johnson & Johnson Services, Inc. (Actelion Pharmaceuticals, Ltd.); United Therapeutics Corporation; Pfizer, Inc.; and Gilead Sciences, Inc. The market is consolidated and competitive in nature. The players enjoy the benefit of high entry barriers to other firms due to high price interdependency

Active Pharmaceutical Ingredients Market Worth $286.6 Billion By 2027

The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth.

A steady rise in consumer demand for APIs, especially in developing and under-developed countries, increases the adoption of these products. In addition, strategic collaborations play a key role in the adoption of these ingredients in various regions. For instance, in February 2019, Cipla Inc. partnered with Wellthy Therapeutics Private Limited to combine digital therapeutics and pharmacotherapy for better patient outcomes in cardiovascular diseases and diabetes.

Private and public initiatives to manufacture active pharmaceutical ingredients within their countries, especially in developing countries such as India, is expected to drive the growth of the market. For instance, API production in India is promoted under the “Make in India” initiative.

Presence of prominent players and increasing government initiatives for the development of pharmaceuticals in various regions are also expected to boost the market growth. Increasing consumer awareness and demand for economical and effective treatment strategies, especially in Asia Pacific and Middle East and Africa, are driving the sales channels. In addition, high adoption and growing usage of online pharmacies are likely to drive the e-commerce sales of APIs.

The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. For instance, in March 2019, Dr. Reddy’s Laboratories Ltd. launched XCEED-a B2B customer service portal. The platform was designed to manage the growing demand for generic active pharmaceutical ingredients by significantly increasing operational efficiency.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/active-pharmaceutical-ingredients-market

Further key findings from the report suggest:

  • On the basis of type of synthesis, the synthetic segment dominated the active pharmaceutical ingredients market in 2019 owing to easy availability of raw materials and easier protocols in place for the synthesis of these molecules
  • The biotech segment is estimated to register the highest CAGR owing to higher efficiency of these molecules and increasing demand for biopharmaceuticals
  • Captive manufacturers held the largest share in 2019 due to easy availability of raw materials
  • The merchant manufacturers segment is estimated to witness a lucrative CAGR over the forecast period
  • The generic segment is estimated to register the highest CAGR over the forecast period. The segment is driven by factors such as lower cost and expiration of patents of branded drugs
  • Asia Pacific is estimated to register a significant CAGR of 8.0% owing to the increasing number of pharmaceutical manufacturing plants in the region
  • Some of the key players in the API market are Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim International GmbH; AbbVie Inc.; Merck & Co., Inc.; Cipla Inc.; Albemarle Corporation; Dr. Reddy’s Laboratories Ltd.; Bristol-Myers Squibb Company; Aurobindo Pharma; and Sun Pharmaceutical Industries Ltd.

Excipients Market Size Worth $6.9 Billion By 2025

The global excipients market size is expected to reach USD 6.9 billion by 2025, expanding at a CAGR of 6.02% from 2017 to 2025, according to a new report by Grand View Research, Inc. Globally increasing reach of generic medicines has been a major factor driving market growth. In addition, rising demand for newer excipients owing to the advantages of drug delivery and stability has led to the growth of the market. 

Excipients are essential components for the improvement of overall pharmaceutical activity and performance, both of which directly impact the characteristics of pharmaceutical formulations. An excipient in the right proportion can improve the shelf life and bioavailability of a formulation. These can also be used in drug delivery mechanisms such as sustained release and rapid release drugs.

Polymers were the largest product category in 2016 and are expected to maintain a comparatively moderate growth rate over the forecast period. Microcrystalline cellulose was the leading polymer in this category, accounting for a share of over 26.0% in 2016.

Sugars are expected to observe the fastest growth over the  coming years, exhibiting an estimated CAGR of 5.1% from 2017 to 2025. Sugars can play an instrumental role in increasing solubility, taste masking, dissolution, and drug delivery, which can drive its market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/excipients-market-analysis

Further key findings from the report suggest:

  • The global excipients demand exceeded 600,000 tons in 2016 and is expected to grow at a moderate rate from 2017 to 2025
  • Owing to high market demand, polymer excipients accounted for the largest revenue share in 2016 and the segment can be anticipated to dominate the market for the coming years as well
  • The global demand for sugars excipients was valued at over USD 1 billion in 2016 and is anticipated to witness significant growth over the coming years
  • The Europe polymers market was pegged at 74,000 tons in 2015 and is estimated to reach a total volume of over 100,000 tons by 2025
  • The market in Asia Pacific is projected to witness substantial growth over the course of the forecast period thanks to several development projects undertaken across major economies, especially in newer excipients markets. The regional market is expected to register a CAGR of 6.63% from 2017 to 2025
  • Key market participants include Eastman Chemical Corporation; P&G Chemicals; Avantor Performance Materials, LLC; Huntsman Corporation; BASF SE; Ashland Inc.; FMC Corporation; Roquette; Colorcon Inc.; Lubrizol Corporation; Valeant; JRS Pharma; Shin-Etsu Chemical Co., Ltd.; DFE Pharma; and Finar Limited.

Cannabis Extract Market Worth $28.5 Billion By 2027

The global cannabis extract market size is expected to be valued at USD 28.5 billion by 2027, according to a new report published by Grand View Research, Inc. It is projected to expand at a CAGR of 16.6% over the forecast period. Growing legalization of cannabis in various countries, preference for cannabis oil and tinctures, and adoption of medical marijuana for treating chronic diseases like arthritis, anxiety, and Alzheimer’s are the major factors propelling the growth.

Cannabis extracts have gained wide recognition in recent years and are expected to provide impetus to cannabis market growth. Based on product type, cannabis extracts are classified into oils and tinctures. The oils segment is expected to dominate the market in 2019 with a revenue of USD 4.8 billion and is anticipated to witness the fastest CAGR of 17.5%, over the forecast period.

Based on extract type, the market is segmented into full spectrum cannabis extracts and cannabis isolates. The full spectrum cannabis extracts dominated the market in 2019, with a revenue of USD 4.3 billion, owing to the added advantage of the entourage effect. Various manufacturers prefer full spectrum cannabis products owing to their advantages over the isolates. Thus, the segment is expected to remain dominant over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cannabis-extract-market

Further key findings from the report suggest:

  • In 2019, oils held the largest revenue share of 66.5% owing to ease of availability and low price of the product
  • The full spectrum segment was valued at USD 4.3 billion in 2019, owing to its entourage effect-a synergistic relationship between cannabinoids and terpenes that exhibits an increase in the healing properties of each cannabinoid
  • Marijuana isolates is anticipated to emerge as the second largest type segment over the forecast period, owing to several advantages that have increased its adoption. For instance, the purest form of isolates, such as CBD oil, have no psychoactive effects as they have no THC content
  • In 2019, North America accounted for the largest share in the global cannabis concentrates market. This can be attributed to high utilization owing to government approvals
  • Key players operating in the cannabis extract market include Canopy Growth Corporation; Aphria Inc.; Aurora Cannabis; Maricann Inc.; Tilray; Organigram Holdings Inc.; Tikun Olam, Ltd.; and The Cronos Group

Peri-implantitis Market Size Worth $1.3 Billion By 2027

The global peri-implantitis market size is expected to reach USD 1.3 billion by 2027, expanding at a CAGR of 8.7%, according to a new report by Grand View Research, Inc. Peri-implantitis is a site-specific destructive inflammatory disease affecting soft and hard tissues around osseointegrated implants, causing a decrease in bone volume and formation of peri-implant pockets. The success rate of dental implants was reported to be 92%–98% over a period of 10 years. Yet, factors like increasing patients with a history of periodontitis, the advent of technological advancement pertaining to efficient treatment of peri-implantitis, and a rise in the patient population prone to smoking and diabetes are fueling the market growth.

The prevalence of peri-implant complication is expected to be on the rise with the increased number of implants being placed around the globe. According to NCBI, in the U.S. from 1999 to 2017, per year 14.0% increase in implant prevalence was recorded. Annually there are about 2,60,000 implants placed in the U.K., which indicates the growing demand for dental implants. As implants are becoming a common treatment, associated disease prevalence including peri-implant mucositis and peri-implantitis shows a positive correlation. Moreover, according to the CDC, 47.2% of adults aged 30 years in the U.S suffered from some form of periodontal disease in 2019. The condition is more common in men than women as they are more prone to smoking and health conditions like diabetes. Advancements like laser debridement, guided bone regeneration (GBR), and diagnostic genetic biomarker technique are expected to boost peri-implantitis treatment market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/peri-implantitis-market

Further key findings from the report suggest:

  • The surgical segment dominated the market in 2019 due to the fact that surgical debridement procedures are efficient and are considered as the most effective technique to treat peri-implantitis
  • Laser debridement non-surgical technique is anticipated to witness the highest growth over the forecast period as it has improved clinical outcomes are efficient due to selective calculus removal
  • Europe dominated the market in 2019 owing to the rising technological advancements for peri-implantitis treatment
  • In the Asia Pacific, the market is expected to witness the highest CAGR over the forecast period owing to the growing geriatric patient population, rising awareness about dental implants and associated disease, and rapid technological advancements.

North America, Europe & Asia Pacific Legal Cannabis Market Worth $67.7 Billion By 2026

The North America, Europe, and Asia Pacific legal cannabis market size is anticipated to reach USD 67.7 billion by 2026, registering a CAGR of 19.6% during the forecast period, according to a new report by Grand View Research, Inc. The increased adoption of hemp and marijuana products coupled with the rising demand for medical marijuana is anticipated to drive the market growth. Furthermore, the impending legalization of marijuana for adult use is an important factor supporting the growth over the forecast period.

Based on product type, marijuana dominated the market with a revenue share of USD 96.6% in 2019. The use of marijuana for medical purposes is gaining momentum owing to recent legalizations in various countries. Marijuana is used for the treatment of patients with chronic conditions such as Parkinson’s disease, cancer, arthritis, Alzheimer’s disease, neurologic problems like depression, anxiety, epilepsy, and others. Thus, wide application of marijuana for the treatment of various chronic conditions is one of the major factors driving the growth of this segment.

Based on application, medical use segment dominated the market with the revenue share of 66.0% in 2019. The medical use of cannabis is legal in a greater number of countries as compared to adult-use, owing to which the segment is expected to remain dominant throughout the forecast period. On the other hand, B2B channels segment is expected to witness the fastest CAGR over the forecast period. The growing use of cannabis and its derivates in various applications areas such as pharmaceuticals, nutraceuticals, personal care and cosmetics, and edibles, is anticipated to boost the demand for these products.

North America dominated the market in 2019 with a revenue share of 91.0%. The early legalization of marijuana for medical and adult-use and the presence of a large customer pool in the region are the key factors driving the market growth. On the other hand, Asia Pacific is expected to be the fastest-growing region, owing to rising awareness regarding the medical and health benefits of cannabis, encouraging the Asian countries to legalize cannabis and its derivatives.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/north-america-europe-asia-pacific-legal-cannabis-market

Further key findings from the study suggest:

  • Marijuana emerged as leading product segment in 2019 with a revenue share of 96.6%, owing to the growing adoption of marijuana for various medical conditions
  • B2B channel is anticipated to be the fastest-growing application segment, owing to the increasing use of cannabinoids for a wide range of industries
  • North America accounted for the largest share, owing to the higher consumption rate due to legal acceptance of cannabis
  • Some of the key players include Aphria, Inc.; Canopy Growth Corporation, Aurora Cannabis, Maricann Group, Inc.; ABcann Medicinals, Inc.; Tilray, The Cronos Group, GW Pharmaceuticals, plc., Organigram Holding, Inc.; and Lexaria Bioscience Corp

GLP-1 Receptor Agonist Market Size Worth $18.2 Billion By 2027

The global GLP-1 receptor agonist market size is expected to reach USD 18.2 billion by 2027, expanding at a CAGR of 6.1%, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.

Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai’s proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.

The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.

The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market

Further key findings from the report suggest:

  • Trulicity was the largest revenue-generating segment in 2019 owing to high prescription rate
  • Ozempic is expected to witness the fastest growth rate over the forecast period due to the benefits like cardiovascular risk reduction, weight loss, and controlled HbA1C levels
  • North America was the largest revenue-generating region in 2019, followed by Europe. The main factors contributing to their growth are increased usage of GLP-1 products, increasing R&D expenditure by government, and well-established biopharmaceutical and pharmaceutical industry in U.S. and Canada
  • Asia Pacific is expected to be the fastest-growing region over the forecast period due to the increasing prevalence of diabetes that supports the uptake of the medication
  • The key market players are adopting strategies such as mergers and acquisitions, product development, product extension, and regional expansion to increase their market share.